Abstracts Archive - Page 1706 of 2607 - ACR Meeting Abstracts

Abstract Number: 1602 • 2016 ACR/ARHP Annual Meeting
Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8 Years
Janet Pope¹, Edward Keystone², Shahin Jamal³, Lisy Wang⁴, Lara Fallon⁵, John Woolcott⁵, Irina Lazariciu⁶ and Boulos Haraoui⁷, ¹Western University, London, ON, Canada, ²Mount Sinai Hospital, Toronto, ON, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Canada, Montreal, QC, Canada, ⁶Quintiles, Saint-Laurent, QC, Canada, ⁷Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Open-label, long-term extension (LTE) studies enrolled tofacitinib-treated patients (pts) to evaluate safety and…
Abstract Number: 1603 • 2016 ACR/ARHP Annual Meeting
Clinical Responses to Tocilizumab Analyzed By Serologic Status in Rheumatoid Arthritis
Laura Cappelli¹, J. Lynn Palmer² and Clifton Bingham III³, ¹Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²CORRONA Research Foundation, Phoenix, AZ, ³Johns Hopkins University, Baltimore, MD
Clinical Responses to Tocilizumab Analyzed by Serologic Status in Rheumatoid Arthritis Background/Purpose: Biologic medications have improved outcomes for patients with rheumatoid arthritis (RA), but little…
Abstract Number: 1604 • 2016 ACR/ARHP Annual Meeting
a First-in-Human Study of CR6086, a New Potent EP4 Prostanoid Receptor Antagonist, Demonstrates Good Safety and Tolerability at Therapeutically Relevant Exposures
Stefano Persiani¹, Carla Manzotti¹, Cristina Vitalini¹, Giampaolo Giacovelli², Federica Girolami¹, Massimo D'Amato¹, Gianfranco Caselli¹ and Lucio C. Rovati^2,3, ¹Rottapharm Biotech, Monza, Italy, ²Clinical Research Department, Rottapharm Biotech, Monza, Italy, ³University of Milano Bicocca, Milano, Italy
Background/Purpose: CR6086 is a potent and selective antagonist of the prostaglandin EP4 receptor. EP4 receptors have a role in T-cell differentiation and expansion, and thus…
Abstract Number: 1605 • 2016 ACR/ARHP Annual Meeting
Pooled Safety and Efficacy of Sarilumab in Rheumatoid Arthritis Patients 65 Years of Age and Older
Roy Fleischmann¹, Mark C. Genovese², Janet van Adelsberg³, Erin Mangan⁴, Melitza Iglesias-Rodriguez⁵, Deborah Dukovic⁶ and TWJ Huizinga⁷, ¹Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University Medical Center, Palo Alto, CA, ³Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi Genzyme, Cambridge, MA, ⁶Sanofi Genzyme, Bridgewater, NJ, ⁷Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Sarilumab (150 or 200 mg every 2 weeks [q2w] subcutaneously) + MTX demonstrated efficacy vs placebo…
Abstract Number: 1606 • 2016 ACR/ARHP Annual Meeting
Metrotexate Treatment Inmunomodulate the Abnormal Cytokine Expression Present in NaïVe Rheumatoid Arthritis Patients
Jorge Monserrat Sanz¹, Ana Maria Gómez Lahoz¹, Maria Dolores Sosa Reina¹, Cristina Bohórquez Heras², Atusa Movasat², Ana Pérez Gómez², Lucía Ruiz Gutiérrez², Ana Sánchez Atrio², Eduardo Cuende Quintana², M José León², David Diaz³, Fernando Albarrán Hernández² and Melchor Alvarez-Mon^2,3, ¹Medicine and Medical Specialities, Laboratory of Immune System Diseases, Department of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain, ²University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ³Laboratory of Immune System Diseases, Department of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain
Background/Purpose: Methotrexate (MTX) is the most commonly used DMARD in rheumatoid arthritis (RA) patients. Since the first reports of the efficacy of low-dose MTX in…
Abstract Number: 1607 • 2016 ACR/ARHP Annual Meeting
The Development of a New Anti–Interleukin 6 Blocker for Rheumatoid Arthritis Patients
Alan Glicklich¹, Paul Grayson¹, Christophe Blanchetot², Qing Zhou³ and Anke Kretz-Rommel¹, ¹Bird Rock Bio, Inc, La Jolla, CA, ²Argenx, Ghent, Belgium, ³Genor BioPharma, Shanghai, China
Background/Purpose: While interleukin-6 (IL-6) blockade with monoclonal antibodies is an established, clinically validated mechanism for the treatment of rheumatoid arthritis (RA), the need for significant…
Abstract Number: 1608 • 2016 ACR/ARHP Annual Meeting
Lack of Early Change in Disease Activity Score Predicts the Likelihood of Achieving Low Disease Activity at Month 6: Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis
Edward Keystone¹, Ronald F van Vollenhoven², Bethanie Wilkinson³, Lara Fallon⁴, Lie-Ju Hwang⁵, Douglass Chapman⁵, Ryan DeMasi⁵ and Eun Bong Lee⁶, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ³Pfizer Inc, Groton, CT, ⁴Pfizer Canada, Montreal, QC, Canada, ⁵Pfizer Inc, New York, NY, ⁶Seoul National University, Seoul, Korea, Republic of
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Treatment guidelines recommend targeting remission or low disease activity (LDA), herein…
Abstract Number: 1609 • 2016 ACR/ARHP Annual Meeting
Efficacy of Tofacitinib in Patients Who Are Inadequate Responders to Disease-Modifying Antirheumatic Drugs According to Early Versus Late Duration of Rheumatoid Arthritis: Post-Hoc Analysis of Data from Phase 3 Trials
Stephen Hall¹, Peter Nash², Maureen Rischmueller³, Zirke Wiid⁴, David Witcombe⁵, David Gruben⁶, Ryan DeMasi⁷ and Tatjana Lukic⁷, ¹Cabrini Medical Centre, Monash University, Melbourne, Australia, ²University of Queensland, Brisbane, Australia, ³The Queen Elizabeth Hospital, Adelaide, Australia, ⁴Pfizer Australia, Sydney, Australia, ⁵Pfizer Australia, Sydney, NSW, Australia, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc analysis of data from Phase 3 studies investigated the efficacy…
Abstract Number: 1610 • 2016 ACR/ARHP Annual Meeting
Safety, Tolerability, and Dose-Dependent Inhibition of T-Cell-Dependent Antibody Response with MEDI4920, a Novel, Engineered CD40L Antagonist: Results of a Single-Ascending Dose Study in Healthy Volunteers
Marius Albulescu¹, Jim Bush², Firas Almazedi², Ethan Grant³, Alex Godwood¹, Robert Miday⁴, Krista Arbaugh⁴, Lisa H. Butler¹, Michele Gunsior⁴, Jing Li⁵ and David Howe¹, ¹MedImmune, Cambridge, United Kingdom, ²Covance Clinical Research Unit, Leeds, United Kingdom, ³Translational Medicine, MedImmune, Gaithersburg, MD, ⁴MedImmune, Gaithersburg, MD, ⁵MedImmune, Mountain View, CA
Background/Purpose: The CD40L/CD40 co-stimulatory pathway is important for T-cell-dependent antibody production. Previous clinical programs with intact monoclonal antibodies against CD40L have been discontinued due to…
Abstract Number: 1611 • 2016 ACR/ARHP Annual Meeting
In Vitro Cellular Profiling of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Reveals a Distinct Phenotypic Signature Compared to Tocilizumab, an Anti–IL-6 Receptor Monoclonal Antibody
Konstantia-Maria Chavele¹, Debbie Gardner², Matthew J Loza², Bidisha Dasgupta², Martin Sims¹, David Shealy², Juliet Reid¹ and Ravi Rao¹, ¹GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, ²Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: IL-6 plays a central pathogenic role in rheumatoid arthritis (RA). IL-6 signals through a complex of transmembrane IL-6R or soluble IL-6R (sIL-6R) with gp130…
Abstract Number: 1612 • 2016 ACR/ARHP Annual Meeting
Abatacept Targets T Follicular Helper Cells in Patients with Rheumatoid Arthritis
Shingo Nakayamada¹, Satoshi Kubo², Maiko Yoshikawa², Yusuke Miyazaki², Ippei Miyagawa³, Shigeru Iwata⁴, Kazuhisa Nakano⁵, Kazuyoshi Saito^6,7 and Yoshiya Tanaka⁸, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵The First department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, KItakyushu, Japan, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: In the pathogenesis of rheumatoid arthritis (RA), T cells can differentiate into functionally distinct subsets, leading to the persistent inflammation and immune abnormality associated…
Abstract Number: 1613 • 2016 ACR/ARHP Annual Meeting
Safe and Effective Tocilizumab Therapy in Elderly Patients with Rheumatoid Arthritis
Christof Specker¹, Jörg Kaufmann², Herbert Kellner³, Peter Kaestner⁴, Christoph Volberg⁵, Verena Braunewell⁶, Martin Aringer⁷, Maren Sieburg⁸, Lothar Meier⁹, Michael Hofmann¹⁰, Jan-Paul Flacke¹¹, Hans-Peter Tony¹² and Gerhard Fliedner¹³, ¹Rheumatology & Clinical Immunology, University Hospital Essen, Essen, Germany, ²Ambulant Centres for Rheumatology, Ludwigsfelde, Germany, ³Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, ⁴Outpatient department of Rheumatology, MVZ Ambulantes Rheumazentrum, Erfurt, Germany, ⁵Rheumazentrum Neuss, Neuss, Germany, ⁶Schwerpunktpraxis Rheumatologie, Moenchengladbach, Germany, ⁷Rheumatology, Medicine III, University Clinical Center Technical University of Dresden, Dresden, Germany, ⁸Rheumatologische Gemeinschaftspraxis, Magdeburg, Germany, ⁹Gemeinschaftspraxis für Innere Medizin - Rheumatologie, Hofheim am Taunus, Germany, ¹⁰Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ¹¹Rheumatology, Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹²Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ¹³Internal Med/Rheumatology, Rheumatological Practice, Osnabrueck, Germany
Background/Purpose: The non-interventional study ICHIBAN was set up in 2010 to evaluate the effectiveness and safety of intravenously administered Tocilizumab (TCZ IV) in patients (pts)…
Abstract Number: 1614 • 2016 ACR/ARHP Annual Meeting
Monotherapy with Abatacept, Rituximab or Tocilizumab Is Not Associated with a Significantly Lower Long Term Retention Than Combination with Synthetic DMARD: Long-Term Registry Data in 4498 Real-Life Patients with Rheumatoid Arthritis
Jacques-Eric Gottenberg¹, Jacques Morel², Arnaud Constantin³, Thomas Bardin⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Alain Saraux⁹, Thierry Schaeverbeke¹⁰, Jean Sibilia¹¹, Martin Soubrier¹², Olivier Vittecoq¹³, Elodie Perrodeau¹⁴, Philippe Ravaud¹⁵, Xavier Mariette¹⁶ and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ³Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁴Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁵Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ⁶Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Rheumatology, Paris Descartes University, Paris, France, ⁸Rheumatology, University Hospital, Lille, France, ⁹Rheumatology, Brest University Hospital, Brest, France, ¹⁰Rheumatology, CHU Bordeaux, Bordeaux, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹³Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁴Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁵Epidemiologist, PARIS, France, ¹⁶Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France
Background/Purpose: Data are very limited concerning the association between cotreatment with a conventional synthetic DMARD (csDMARD) and long term retention of abatacept (ABA), rituximab (RTX) and tocilizumab…
Abstract Number: 1615 • 2016 ACR/ARHP Annual Meeting
Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Significantly Improves Physical Function and Reduces Morning Stiffness in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global, Randomized, Placebo-Controlled, Phase 3 Trial
Yoshiya Tanaka¹, Clifton Bingham III², Daniel Aletaha³, Prasheen Agarwal⁴, Sharon Popik⁴, Regina Kurrasch⁵, Steve Peterson⁴, Rita Ganguly⁵, Chenglong Han⁴ and Kelly McQuarrie⁴, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, Collegeville, PA
Background/Purpose: Improvement in physical function and morning stiffness are key goals of rheumatoid arthritis (RA) treatment. Sirukumab, a selective human anti–IL6 monoclonal antibody, has recently…
Abstract Number: 1616 • 2016 ACR/ARHP Annual Meeting
Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α Monoclonal Antibody: Long-Term Safety and Efficacy for up to 158 Weeks of Treatment in Patients with Rheumatoid Arthritis
GR Burmester¹, IB McInnes², JM Kremer³, P Miranda⁴, J Vencovský⁵, A Godwood⁶, M Albulescu⁶, D Close^⁶ and Michael Weinblatt⁷, ¹Charité – University Medicine Berlin, Berlin, Germany, ²University of Glasgow, Glasgow, United Kingdom, ³The Albany Medical College, Albany, NY, ⁴Centro De Estudios Reumatológicos, Santiago, Chile, ⁵Charles University, Prague, Czech Republic, ⁶MedImmune, Cambridge, United Kingdom, ⁷Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Inhibition of GM–CSFR-α is a novel approach to treat RA. Mavrilimumab, an investigational human monoclonal antibody targeting GM–CSFR-α, has demonstrated efficacy and an acceptable…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].